Lima Memorial Health System, a leader in infection prevention, has welcomed Tru-D SmartUVC as its most recent investment in patient safety and quality of care.
According to the Centers for Disease Control and Prevention, hospital-acquired infections affect 2 million people every year, resulting in nearly 100,000 deaths and $30 billion in medical costs. Although hospitals strive to adhere to stringent infection prevention guidelines, human error is inevitable. However, Tru-D eliminates human error and takes the guesswork out of room disinfection, especially in patient areas where hospital-acquired infections are a risk. Lima Memorial plans to use the robot before every surgery at the hospital and eventually in the hospital's isolation rooms.
PotashCorp, the world's largest crop nutrient company, stepped forward to partner with Lima Memorial for the purchase of a Tru-D Smart UVC. "You can't stand still in healthcare, and PotashCorp's gift has enabled us to make a leap into the future with cutting-edge technology to virtually eliminate infections," says Mike Swick, president and CEO of Lima Memorial Health System.
Tru-D precisely measures reflected UVC emissions with Sensor360™ technology and automatically calculates the pathogen-lethal UV dose required to terminally disinfect each room, dynamically compensating for room size, shape and other dose-altering variables, including position of contents, windows, blinds and doors. Additionally, Tru-D tracks disinfection outcomes through its iTru-D feature, which provides real-time visual usage data, including disinfection times, progress, dose delivery and location, through a cloud-based portal.
The ECRI Institute named disinfecting robots as the No. 1 technology in the Top 10 Hospital C-Suite Watch List for 2015. And, by no coincidence, the highly anticipated results of the most comprehensive UV disinfection study to date, Benefits of Enhanced Terminal Room Disinfection performed by the Duke Infection Control Outreach Network, are due out later this year. Tru-D was selected as the exclusive device for this $2 million landmark study, which was funded by the CDC.
"Lima Memorial has shown its commitment to infection prevention, translating into healthier patients. We're proud that Tru-D can help them continue this commitment," says Chuck Dunn, president and CEO of Tru-D SmartUVC LLC. "This is clearly an organization focused on innovation and proven results, and with the robot's ability to achieve 99.99 percent disinfection, Tru-D will further this focus."
Lima Memorial Health System joins a growing roster of leading healthcare institutions that have invested in the technology, including UNC Health Care, Walter Reed Army Medical Center and the National Institutes of Health.
Source: Tru-D SmartUVC
The Evolution of Health Care Environmental Hygiene: A Long Overdue Shift in Infection Control
September 5th 2024This new column, Clean Hospital with Alexandra Peters, PhD, explores advancements in health care environmental hygiene, highlighting its growing recognition as a key component of infection prevention and honoring pioneers like Professor Stephanie Dancer.
New UV-C Disinfection Technology for Ultrasound Probes Earns FDA Clearance
September 4th 2024Chronos, a chemical-free UV-C disinfection device for ultrasound probes, received FDA clearance. It offers health care professionals a fast, automated solution to reduce cross-contamination and improve infection prevention.
Infection Intel: Augmenting SHIELD WALL Modular Containment Systems by Abatement Technologies
August 8th 2024Jackie Otero, senior territory sales representative at Abatement Technologies, discusses the SHIELD WALL modular containment system by Abatement Technologies, highlighting its quick assembly, durability, noise reduction, and benefits in maintaining indoor air quality in health care settings.
Phage Therapy: The Future of Bacterial Infection Treatment?
August 7th 2024Rising antibiotic resistance necessitates exploring phage therapy as an alternative. Despite historical sidelining, phages show promise in treating various infections, but regulatory, safety, and resistance challenges remain.